The association between mental illness, psychotropic medication use and hypertensive disorders in pregnancy: A multicentre study

2021 ◽  
Vol 24 ◽  
pp. 22-26
Author(s):  
Jacqueline Frayne ◽  
Stuart Watson ◽  
Martien Snellen ◽  
Thinh Nguyen ◽  
Megan Galbally
Keyword(s):  
Mental Illness ◽  
Multicentre Study ◽  
Psychotropic Medication ◽  
Medication Use ◽  
Hypertensive Disorders ◽  
Hypertensive Disorders In Pregnancy ◽  
In Pregnancy

Prevalence and Risk Factors of Hypertensive Disorders in Pregnancy: Case of Mezam Division, NWR Cameroon

2020 ◽  
Vol 03 (03) ◽  
Author(s):  
Nkem Ernest Njukang ◽  
Tah Aldof Yoah ◽  
Martin Sama ◽  
Thomas Obinchemti EGBE ◽  
Joseph Kamgno
Keyword(s):  
Risk Factors ◽  
Hypertensive Disorders ◽  
Hypertensive Disorders In Pregnancy ◽  
In Pregnancy

scholarly journals Prevalence and determinants of chronic kidney disease in women with hypertensive disorders in pregnancy in Nigeria: a cohort study

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Salisu M. Ishaku ◽  
Timothy Olusegun Olanrewaju ◽  
Joyce L. Browne ◽  
Kerstin Klipstein-Grobusch ◽  
Gbenga A. Kayode ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Gestational Hypertension ◽  
Monitoring Program ◽  
Sub Saharan Africa ◽  
Future Research ◽  
Hypertensive Disorders ◽  
Hypertensive Disorders In Pregnancy ◽  
Sub Saharan ◽  
In Pregnancy

Abstract Background Worldwide, hypertensive disorders in pregnancy (HDPs) complicate between 5 and 10% of pregnancies. Sub-Saharan Africa (SSA) is disproportionately affected by a high burden of HDPs and chronic kidney disease (CKD). Despite mounting evidence associating HDPs with the development of CKD, data from SSA are scarce. Methods Women with HDPs (n = 410) and normotensive women (n = 78) were recruited at delivery and prospectively followed-up at 9 weeks, 6 months and 1 year postpartum. Serum creatinine was measured at all time points and the estimated glomerular filtration rates (eGFR) using CKD-Epidemiology equation determined. CKD was defined as decreased eGFR< 60 mL/min/1.73m2 lasting for ≥ 3 months. Prevalence of CKD at 6 months and 1 year after delivery was estimated. Logistic regression analyses were conducted to evaluate risk factors for CKD at 6 months and 1 year postpartum. Results Within 24 h of delivery, 9 weeks, and 6 months postpartum, women with HDPs were more likely to have a decreased eGFR compared to normotensive women (12, 5.7, 4.3% versus 0, 2 and 2.4%, respectively). The prevalence of CKD in HDPs at 6 months and 1 year postpartum was 6.1 and 7.6%, respectively, as opposed to zero prevalence in the normotensive women for the corresponding periods. Proportions of decreased eGFR varied with HDP sub-types and intervening postpartum time since delivery, with pre-eclampsia/eclampsia showing higher prevalence than chronic and gestational hypertension. Only maternal age was independently shown to be a risk factor for decreased eGFR at 6 months postpartum (aOR = 1.18/year; 95%CI 1.04–1.34). Conclusion Prior HDP was associated with risk of future CKD, with prior HDPs being more likely to experience evidence of CKD over periods of postpartum follow-up. Routine screening of women following HDP-complicated pregnancies should be part of a postpartum monitoring program to identify women at higher risk. Future research should report on both the eGFR and total urinary albumin excretion to enable detection of women at risk of future deterioration of renal function.

Subsequent risk of gout for women with hypertensive disorders in pregnancy

2016 ◽  
Vol 34 (5) ◽  
pp. 914-919 ◽  
Author(s):  
I-Kuan Wang ◽  
Jiunn-Horng Chen ◽  
Chih-Hsin Muo ◽  
Che-Yi Chou ◽  
Yao-Lung Liu ◽  
...  
Keyword(s):  
Hypertensive Disorders ◽  
Hypertensive Disorders In Pregnancy ◽  
In Pregnancy ◽  
Subsequent Risk

A Systematic Review on Outcomes of Preterm Small for Gestational Infants Born to Women With Hypertensive Disorders in Pregnancy

2021 ◽  
Vol 35 (4) ◽  
pp. E58-E68
Author(s):  
Forgive Avorgbedor ◽  
Kaboni W. Gondwe ◽  
Baiming Zou ◽  
Jamie L. Conklin ◽  
Seonae Yeo
Keyword(s):  
Systematic Review ◽  
Hypertensive Disorders ◽  
Hypertensive Disorders In Pregnancy ◽  
In Pregnancy

scholarly journals Management of hypertensive disorders in pregnancy in Black women: a systematic review

2021 ◽  
Author(s):  
Jeeva John ◽  
Gwenetta Curry
Keyword(s):  
Systematic Review ◽  
Black Women ◽  
Randomised Control Trial ◽  
Free Text ◽  
Hypertensive Disorders ◽  
Black Patients ◽  
Study Results ◽  
Hypertensive Disorders In Pregnancy ◽  
Randomised Control Trials ◽  
In Pregnancy

Abstract Background: Black women are four times more likely to die than White women due to complications during pregnancy or childbirth in the U.K. This cohort are also more prone to Hypertensive Disorders in Pregnancy (HDP). Outside of pregnancy, there are race based differences in the management of hypertension as Calcium-Channel Blockers (CCB) 9 are more effective in reducing blood pressure in Black patients. It is unclear whether these differences in anti-hypertensive management extend to the management of hypertension in pregnancy. The primary objective was to address this gap in evidence by undertaking a systematic review of all randomised control trials investigating pharmacological management of HDP to assess whether CCBs are the most effective anti-hypertensive agent in Black pregnant women. Methods: The following electronic databases were searched: PubMed, MEDLINE and Embase. We used MeSH and free text terms in conjunction to increase sensitivity to potentially relevant studies. Inclusion criteria included: (1) study involved treatment of HDP; (2) study was of a randomised control trial design; (3) one of the treatment arms involved CCBs and (4) English full-text. Information regarding baseline participant data, type of anti-hypertensive, and clinical outcomes was extracted from each study. Results: This review highlighted four randomised control trials, which published race or ethnicity demographics, with only one trial that stratified HDP outcomes by ethnicity. Conclusions: There is a lack of evidence to draw definite conclusions as to whether CCBs are the most effective anti-hypertensive agent for Black patients with HDP, highlighting the need for further research in this area. However, this review demonstrates some evidence to support the hypothesis that CCBs could be more effective in the management of HDP in Black patients and that Labetalol, which is the current first-line management of HDP, may not represent the gold standard of treatment in this cohort.

Sign in / Sign up

Export Citation Format

Share Document